A self-directed learning material to complete in your own time. With the learning module, you can learn about the unmet needs in CCA, discuss the need for molecular profiling for early patient identification and learn more about PEMAZYRE.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions to their local authority or to Incyte (by e-mail: firstname.lastname@example.org).
Intended for licensed healthcare professionals located in Finland.
You are now leaving the Incyte PEMAZYRE website. This link will take you to a site that is not owned or maintained by Incyte. Incyte is not responsible for the information contained on third–party sites. Would you like to continue?